Arbutus Biopharma Corporation develops infectious-disease therapeutics centered on chronic hepatitis B, including imdusiran (AB-729), a GalNAc-conjugated RNAi therapeutic, and AB-101, an oral PD-1 inhibitor. News for ABUS commonly covers clinical data, regulatory designations such as FDA Fast Track for imdusiran, scientific-meeting abstracts, and corporate updates tied to the company’s cHBV programs.
Recurring coverage also includes financial results, capital-allocation updates, licensing revenue from lipid nanoparticle technology, and intellectual-property developments involving Arbutus and its licensee Genevant Sciences. The company’s LNP delivery technology and related patent matters are a recurring business theme alongside its clinical-stage antiviral pipeline.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced positive results from its Phase 1a/1b clinical trial of AB-729, aimed at treating chronic hepatitis B virus (HBV) infection. The study showed a mean 0.99 log10 IU/mL reduction in HBsAg at week 12 with normal liver enzyme levels. The company is now advancing to multi-dose cohorts, dosing 60 mg of AB-729, and plans to release further data in late 2020. Interim findings suggest AB-729 is both effective and well-tolerated, supporting the goal of a combined therapy for chronic HBV.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced that CEO William Collier will present at the UBS Virtual Global Healthcare Conference on May 19, 2020, at 11:40 AM ET. Interested parties can access the live webcast through the company's website. An archived replay will be available after the conference. Arbutus focuses on developing a cure for chronic hepatitis B virus (HBV) infection with multiple drug candidates.